Instructors
Alicia Li
, Health Canada, Canada
Alicia Li holds a Master of Biotechnology from the University of Toronto and a Bachelor of Science from McGill University. Prior to starting her 10-year career at Health Canada, she completed internships at sanofi Pasteur, AstraZeneca Canada and GlaxoSmithKline in various roles including regulatory affairs and international clinical study management. She is currently a Senior Policy Analyst in the Office of Legislative and Regulatory Modernisation. She has led the implementation of several key legislative and regulatory proposals within the Health Products and Food Branch. She also worked as a Regulatory Project Manager at the Therapeutic Products Directorate and a Senior Policy Advisor in the Biologics and Genetic Therapies Directorate.
Kristin Willemsen, MS
Vice President, Scientific & Regulatory Affairs, Food, Health & Consumer Products of Canada, Canada
Kristin Willemsen is the Vice President of Scientific and Regulatory Affairs at Food, Health & Consumer Products Canada. Since 2008, she has been working with members to influence the regulation, policy and administration of over-the-counter drugs and natural health products. Kristin earned a Masters of Science from the University of Ottawa and is a Certified Association Executive.
Marilena Bassi, MA
Senior Executive Director, Therapeutic Products Directorate, Health Canada, Canada
Marilena Bassi has been with Health Canada since 2004 where she has held various policy, evaluation and performance management related positions. Currently she is the Senior Executive Director of the Therapeutic Products Directorate at Health Canada.
Ruth Hansson
Policy Analyst, Health Canada, Canada
Ruth Hansson has worked at Health Canada for over 15 years in the policy office at the Biologics and Genetic Therapies Directorate. In her role as Policy Analyst, she specializes in the guidance development process from concept to publication.
Nadia Giancaspro
Senior Policy Analyst, Health Canada, Canada
Nadia Giancaspro has been with Health Canada since 2001. She is a Senior Policy Analyst within the Therapeutics Directorate of the Health Products and Food Branch. Her latest work has been focused on the development of regulations, policies and guidance on issues related to special access to drugs in Canada, the opioid crisis, H1N1, and other emergency-related issues.